Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + lenvatinib first-line for unresectable or metastatic hepatitis B-associated hepatocellular carcinoma
ChiCTR2300077912Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300077912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077912.